Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: A 3-year naturalistic follow-up study

Journal of Clinical Psychiatry

Volumn 77, Issue 4, 2016, Pages 492-500

  Mayoral Van Son, Jacqueline ^a,b,c   Ortiz Garcia De La Foz, Victor ^b,c,d   Martinez Garcia, Obdulia ^d   Moreno, Teresa ^e   Parrilla Escobar, Maria ^f   Valdizan, Elsa M ^b,c   Crespo Facorro, Benedicto ^b,c,d  

^a HOSPITAL SIERRALLANA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e Osakidetza Mental Health Network   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISABILITY ASSESSMENT SCHEDULE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; EFFECTIVE DOSE (PHARMACOLOGY); FEMALE; FIRST EPISODE NONAFFECTIVE PSYCHOSIS; FUNCTIONAL STATUS ASSESSMENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RECURRENCE RISK; RELAPSE; REMISSION; RISK ASSESSMENT; RISK FACTOR; SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOM; SCHIZOPHRENIA; SPAIN; SYMPTOM; SYMPTOM ASSESSMENT; TIME TO RELAPSE; TREATMENT DURATION; TREATMENT WITHDRAWAL; ADULT; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; RECURRENT DISEASE; SUBSTANCE WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECURRENCE; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84966461423     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09540     Document Type: Article

References (36)

1. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071. doi:10.1016/S0140-6736(12)60239-6 PubMed
2. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand suppl. 2009;119(438):7-14. doi:10.1/j.160-047.208.01308.x PubMed
3. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. doi:10.101/archpsyc.56.3.241 PubMed
4. Caseiro O, Pérez-Iglesias R, Mata I, et al. Predicting relapse after a first episode of nonaffective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46(8):1099-1105. doi:10.1016/j.jpsychires.2012.05.01 PubMed
5. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry. 1995;52(3):173-188. doi:10.101/archpsyc.195.03950150501 PubMed
6. Takeuchi H, Suzuki T, Uchida H, et al. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012;134(2-3):219-225. doi:10.1016/j.schres.201.1.021 PubMed
7. Kissling W, ed. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Berlin, Heidelberg, Germany: Springer; 1991. doi:10.107/978-3-642-8692-8
8. Zipursky RB. Why are the outcomes in patients with schizophrenia so poor? J Clin Psychiatry. 2014;75(suppl 2):20-24. doi:10.408/JCP.13065su1.05 PubMed
9. The Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry. 1998;43(suppl 2):25S-40S. PubMed
10. Wunderink L, Nieboer RM, Wiersma D, et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913-920. doi:10.101/jamapsychiatry.2013.19 PubMed
11. Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, et al. Epidemiological factors associated with treated incidence of firstepisode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv Psychiatry. 2008;2(3):178-187. doi:10.1/j.1751-7893.208.074.x PubMed
12. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, et al. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of firstepisode nonaffective psychosis. J Clin Psychiatry. 2006;67(10):1511-1521. doi:10.408/JCP.v67n104 PubMed
13. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449. doi:10.176/api.ajp.162.3.41 PubMed
14. Overall J. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10(3):799-812. doi:10.246/pr0.1962.10.3.79
15. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976.
16. Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. Relapse prevention and remission attainment in first-episode non-affective psychosis: a randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine. J Psychiatr Res. 2011;45(6):763-769. doi:10.1016/j.jpsychires.2010.1.02 PubMed
17. Mañá S, Ivorra J. Adaptación y fiabilidad de la entrevista para la evaluación de la discapacidad social en pacientes psiquiátricos (OMS). Rev Psiquiatr Fac Med Barcelona. 1998;25:43-48.
18. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
19. Andreasen NC, ed. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
20. Birchwood M, Smith J, Macmillan F, et al. Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 1989;19(3):649-656. doi:10.1017/S032917024247 PubMed
21. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667. doi:10.408/JCP.v64n0607 PubMed
22. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693. doi:10.176/api.ajp.209.09060802 PubMed
23. Chouinard G, Jones BD. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980;137(1):16-21. doi:10.176/ajp.137.1.16 PubMed
24. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006;114(1):3-13. doi:10.1/j.160-047.206.0787.x PubMed
25. Emsley R, Oosthuizen P, Koen L, et al. Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol. 2013;33(1):80-83. doi:10.1097/JCP.0b013e31827bfc1 PubMed
26. Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75-85. doi:10.1093/oxfordjournals.schbul.a0315 PubMed
27. Emsley R, Chiliza B, Asmal L, et al. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13(1):50. doi:10.186/1471-24X-13-50 PubMed
28. Norman RM, Malla AK. Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull. 1995;21(4):527-539. doi:10.1093/schbul/21.4.527 PubMed
29. Malla A, Norman R, Bechard-Evans L, et al. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med. 2008;38(11):1585-1593. doi:10.1017/S0329170702656 PubMed
30. Gaebel W, Riesbeck M, Wölwer W, et al; German Study Group on First-Episode Schizophrenia. Relapse prevention in firstepisode schizophrenia-maintenance vs intermittent drug treatment with prodromebased early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011;72(2):205-218. doi:10.408/JCP.09m05459yel PubMed
31. Gaebel W, Riesbeck M. Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007;95(1-3):19-29. doi:10.1016/j.schres.207.06.016 PubMed
32. Gaebel W, Frick U, Köpcke W, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry suppl. 1993;(21):8-12. PubMed
33. Zipursky RB, Menezes NM, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014;152(2-3):408-414. doi:10.1016/j.schres.2013.08.01 PubMed
34. Wunderink L, Nienhuis FJ, Sytema S, et al. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654-661. doi:10.408/JCP.v68n0502 PubMed
35. Wunderink L, Sytema S. Early medication discontinuation on long-term recovery outcome in first-episode psychosis-reply. JAMA Psychiatry. 2014;71(2):208-209. doi:10.101/jamapsychiatry.2013.3530 PubMed
36. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286-290. doi:10.1034/j.160-047.202.02437.x PubMed